Expert Interview
Examining Tivdak (tisotumab vedotin) for recurrent or metastatic cervical cancer following chemotherapy progression
Ticker(s): SGENInstitution: City of Hope
"I am also excited about tisotumab vedotin (I have about 15 patients with recurrent/metastatic cervical cancer, I have no yet prescribed it but am excited about it"
- Assistant clinical professor in gynecologic oncology at City of Hope at the South Bay (Torrance, CA) location. Previously partner in Bay Area Gynecology Oncology in San Jose, CA Fellowship training at Magee-Womens Hospital of University of Pittsburgh Medical Center Residency training at NewYork-Presbyterian Hospital - Weill Cornell Medical Center Medical school at Northwestern University Feinberg School of Medicine
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
